Remove Clinical Development Remove Drug Development Remove Pharmaceuticals
article thumbnail

Harnessing AI and Real-World Data: The Future of Clinical Development

PPD

The pharmaceutical industry is currently experiencing a significant transformation. The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. AI technologies are fueling drug discovery and asset and trial ROI optimization.

52
article thumbnail

What is the biggest barrier to rare disease drug development?

Drug Discovery World

Dr Asma Patel , Vice President of Integrated Services for Early Development at Quotient Sciences, reflects on the biggest barriers to rare disease drug development and how companies can overcome these. Utilising an integrated approach for development can improve the likelihood of downstream clinical and commercial success.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lantern Pharma's Pioneering Role in AI-Driven Oncology Drug Development with the RADRĀ® Platform

DrugBank

In the rapidly evolving landscape of oncology drug development, artificial intelligence (AI) has emerged as a revolutionary force, altering not just the pace but the very methodology of discovery and development.

article thumbnail

Navigating the challenges and opportunities of AI in drug development and personalised medicine

Drug Target Review

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. With support from pharmaceutical companies, ultimately, the answer to this question should be yes.

article thumbnail

FSP Engagements Continue to Gain Popularity, Drive Success

PPD

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

article thumbnail

The Power of Personalization Amid the Changing CRO Landscape

Conversations in Drug Development Trends

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture. At Worldwide, we understand that every program is different, which means every drug development path forward will be unique.

article thumbnail

International Womenā€™s Day: Female life science leaders

Drug Discovery World

Dr Thomas has a background in biochemistry research at Leicester, Cambridge, and Glaxo, after which she has had 25 years of pharmaceutical drug discovery and development experience from large Pharma (GSK) and SMEs. See her interview with Megan Thomas at the Avacta Group Open Day.